Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3 ; volume:13 ; number:1 ; day:17 ; month:8 ; year:2023 ; pages:1-15 ; date:12.2023
Scientific reports ; 13, Heft 1 (17.8.2023), 1-15, 12.2023
- Creator
-
Rampuria, Pragya
Mosyak, Lidia
Root, Adam R.
Svenson, Kristine
Agostino, Michael J.
LaVallie, Edward R.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-40467-0
- URN
-
urn:nbn:de:101:1-2024020613234546389229
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rampuria, Pragya
- Mosyak, Lidia
- Root, Adam R.
- Svenson, Kristine
- Agostino, Michael J.
- LaVallie, Edward R.
- SpringerLink (Online service)
Other Objects (12)
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
T-cell surveillance of therapy-induced senescent lymphoma cells in the presence of anti-CD19/CD20 × CD3 bispecific antibodies
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy